Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: In Vitro Optimization and Novel Nanoparticle Delivery Studies

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Hung, Sau Wai ^a   Mody, Hardik ^a   Marrache, Sean ^a   Bhutia, Yangzom D ^a   Davis, Franklin ^a   Cho, Jong Hyun ^a   Zastre, Jason ^a   Dhar, Shanta ^a   Chu, Chung K ^a   Govindarajan, Rajgopal ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; ADENOSINE; GEMCITABINE; GUANOSINE; HISTONE; HISTONE H3; LYSINE; MACROGOL; NANOPARTICLE; POLYGLACTIN; THYMIDINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CHRONOTHERAPY; CONTROLLED RELEASE FORMULATION; DERIVATIZATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; EPITHELIUM CELL; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PANCREAS CANCER; PANCREAS DUCT;

ADENOSINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DEOXYCYTIDINE; DNA METHYLATION; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; NANOPARTICLES; NUCLEOSIDES; PANCREATIC NEOPLASMS; XENOPUS;

EID: 84881157977     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071196     Document Type: Article

References (45)

1. Simon JA, Kingston RE, (2009) Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Bio 10: 697-708.
2. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, et al. (2012) EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metast Rev: 1-9.
3. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, et al. (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218.
4. Bao B, Ali S, Banerjee S, Wang Z, Logna F, et al. (2012) Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression. Cancer Res 72: 335-345.
5. Crea F, Paolicchi E, Marquez VE, Danesi R, (2012) Polycomb genes and cancer: Time for clinical application? CRC Cr Rev Oncol-Hem 83: 184-193.
6. Ougolkov AV, Bilim VN, Billadeau DD, (2008) Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 14: 6790-6796.
7. Chen Y, Xie D, Yin Li W, Man Cheung C, Yao H, et al. (2010) RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett 297: 109-116.
8. Fujii S, Fukamachi K, Tsuda H, Ito K, Ito Y, et al. (2012) RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Biochem Bioph Res Co 417: 1074-1079.
9. Fujii S, Ito K, Ito Y, Ochiai A, (2008) Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332.
10. Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, et al. (2011) EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One 6: e21651.
11. Qazi AM, Aggarwal S, Steffer CS, Bouwman DL, Weaver DW, et al. (2011) Laser Capture Microdissection of Pancreatic Ductal Adeno-Carcinoma Cells to Analyze EzH2 by Western Blot Analysis. Methods Mol Biol 755: 245-256.
12. Toll AD, Dasgupta A, Potoczek M, Yeo CJ, Kleer CG, et al. (2010) Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol 41: 1205-1209.
13. Wei Y, Xia W, Zhang Z, Liu J, Wang H, et al. (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinogen 47: 701-706.
14. Hayden A, Johnson PWM, Packham G, Crabb SJ, (2011) S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Tr 127: 109-119.
15. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, et al. (2011) (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 32: 1525-1532.
16. Tan J, Yang X, Zhuang L, Jiang X, Chen W, et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Gene Dev 21: 1050-1063.
17. Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, et al. (2012) TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). Clin Cancer Res 18: 4201-4212.
18. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, et al. (2011) Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 10: 40.
19. Chase A, Cross NCP, (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618.
20. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, et al. (2011) The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118: 2830-2839.
21. Puppe J, Drost R, Liu X, Joosse S, Evers B, et al. (2009) BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 11: R63.
22. Yang X, Lay F, Han H, Jones PA, (2010) Targeting DNA methylation for epigenetic therapy. Trends in pharmacological sciences 31: 536-546.
23. Wong A, Soo RA, Yong W-P, Innocenti F, (2009) Clinical pharmacology and pharmacogenetics of gemcitabine. Drug metabolism reviews 41: 77-88.
24. Bayraktar S, Bayraktar UD, Rocha-Lima CM, (2010) Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World journal of gastroenterology: WJG 16: 673.
25. Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R, (2011) CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 71: 1825-1835.
26. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
27. Kang N, Jun AH, Bhutia YD, Kannan N, Unadkat JD, et al. (2010) Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem 285: 28343-28352.
28. Govindarajan R, Endres CJ, Whittington D, LeCluyse E, Pastor-Anglada M, et al. (2008) Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am J Physiol-Gastr L 295: G570-G580.
29. Adema A, Radi M, Daft J, Narayanasamy J, Hoebe E, et al. (2007) Troxacitabine prodrugs for pancreatic cancer. Nucleos Nucleot Nucl 26: 1073-1077.
30. Radi M, Adema AD, Daft JR, Cho JH, Hoebe EK, et al. (2007) In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1, 3-dioxolane-cytidine, prodrugs. J Med Chem 50: 2249-2253.
31. Deroose FD, Clercq PJD, (1995) Novel enantioselective syntheses of (+)-biotin. J Org Chem 60: 321-330.
32. Marrache S, Dhar S, (2012) Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci 109: 16288-16293.
33. Paproski RJ, Ng AML, Yao SYM, Graham K, Young JD, et al. (2008) The role of human nucleoside transporters in uptake of 3′-deoxy-3′-fluorothymidine. Mol Pharmacol 74: 1372-1380.
34. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, et al. (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22.
35. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, et al. (2012) Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells. Mol Cancer Ther 11: 1735-1746.
36. Stathis A, Moore M, (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172.
37. Coulombe RA, Sharma R, Huggins J, (1995) Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. Eur J Drug Metab Ph. 20: 197-202.
38. Glazer RI, Hartman KD, Knode MC, Richard MM, Chiang PK, et al. (1986) 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Bioph Res Co 135: 688-694.
39. Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, et al. (2012) EZH2 couples pancreatic regeneration to neoplastic progression. Gene Dev 26: 439-444.
40. Rogenhofer S, Kahl P, Holzapfel S, Von Ruecker A, Mueller SC, et al. (2012) Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res 32: 879-886.
41. Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, et al. (2012) Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res 4: 247.
42. Toth M, Boros IM, Balint E, (2012) Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. Cancer Sci 104: 659-669.
43. Shi L, Sun L, Li Q, Liang J, Yu W, et al. (2011) Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci 108: 7541-7546.
44. Chang C, Hung M, (2011) The role of EZH2 in tumour progression. Brit J Cancer 106: 243-247.
45. Abdel-Wahab O, Levine RL, (2010) EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid Malignancies. Cancer Cell 18: 105-107.